635712-44-6 Usage
General Description
5-Bromo-7-chloro-1H-indazole is a chemical compound with the molecular formula C8H5BrClN2. It is a heterocyclic organic compound that contains both bromine and chlorine atoms. 5-BROMO-7-CHLORO-1H-INDAZOLE has potential applications in medicinal chemistry and pharmaceutical research due to its structural properties. It may be used as a building block for the synthesis of various biologically active molecules, and it could also have potential as a pharmacological agent or drug candidate. Additionally, 5-Bromo-7-chloro-1H-indazole has been studied for its potential use in the development of agrochemicals and pesticides. Overall, this compound is of interest to researchers in the fields of chemistry, biology, and materials science due to its unique structure and potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 635712-44-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,3,5,7,1 and 2 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 635712-44:
(8*6)+(7*3)+(6*5)+(5*7)+(4*1)+(3*2)+(2*4)+(1*4)=156
156 % 10 = 6
So 635712-44-6 is a valid CAS Registry Number.
InChI:InChI=1/C7H4BrClN2/c8-5-1-4-3-10-11-7(4)6(9)2-5/h1-3H,(H,10,11)
635712-44-6Relevant articles and documents
FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR
-
Paragraph 0128; 0132-0134, (2020/08/09)
Disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and an application of the compound or slat in preparation of drugs for treating diseases related to an A2A receptor.
Calcitonin gene related peptide receptor antagonists
-
, (2008/06/13)
The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
